An interventional study of Culturally adapted i-CBT in Depressive Symptoms, Anxiety Symptoms and Grief, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 15 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Depression by Karolinska Institutet — 8 open to participants now, 11 under way, none of them phase 3. Depression · Karolinska Institutet.
Among the 42 studies in Depression by Karolinska Institutet, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, and was the 39th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →8 of the 42 studies in Depression by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Healthy volunteers
Karolinska Institutet · Sites in Sweden
Ages 18+ · Women only
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 15 Years to 29 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 130 across the 34 interventional studies, 140 across the 8 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
2 of the studies in Depression by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06145555Karolinska InstitutetAcute Psychological Sleep Stabilisation for Patients Hospitalised With Depression | 2026-12 |
| NCT06687291Karolinska InstitutetCognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Depression by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this randomized controlled trial (RCT) is to investigate the effectiveness of a culturally adapted internet-based cognitive behavioral therapy (i-CBT) intervention in reducing symptoms of common mental health issues among Farsi/Dari-speaking youth migrants and refugees. Investigator hypothesizes that there will be a significant decrease in psychological symptoms after participants receive the intervention compared to a control group.
Participants who are included in the study will be allocated to the experimental group and the control group (waiting list). Participants will be invited to participate tailored i-CBT intervention over 10-weeks. Intervention covers common psychological issues. Participants will have access to support through a chatting function, during the interventional period. Intervention effects will be measured prior-treatment, post-treatment, and 6 months post-treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tailored I-CBT for mild to moderate common mental health problems over a 10-weeks-period.
Behavioral: Culturally adapted i-CBT
Control group
A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.
Hopkins Symptom Checklist-25 (HSCL-25)
Assessment of anxiety and depressive symptoms. HSCL-25 consists of 25 items.Each item is rated on a scale from 1 to 4, where 1 means "Not at all" and 4 means "Extremely".Higher scores indicate a worse outcome, as they reflect greater severity of symptoms.
Time frame: Pre-intervention, up to 5 weeks, immediately after the intervention, 6 months after completion of the intervention
Psychological Outcome Profiles (PSYCHLOPS)
Impact of problematic area on function. PSYCHLOPS questionnaire consists of 4 items. These items are designed to capture the patient's main problem, the impact of this problem on their daily life, and their overall well-being. Each question in PSYCHLOPS is scored on a scale from 0 to 5, where 0 indicates no problem and 5 indicates the most severe problem. Higher scores indicate a worse outcome, as they reflect greater severity of problems or distress.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
Insomnia Severity Index (ISI)
Assessment of severity of insomnia symptoms. ISI consists of 7 items, each rated on a scale from 0 to 4.Higher scores indicate a worse outcome, as they reflect more severe insomnia symptoms.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
Prolonged Grief Disorder (PG-13)
Assessment of prolonged grief disorder. The PG-13 consists of 13 items, each rated on a scale from 1 to 5, where 1 means "Not at all" and 5 means "Several times a day". Higher scores indicate a worse outcome, as they reflect more severe symptoms of prolonged grief.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
Posttraumatic Stress Disorder Checklist (PCL-5)
Assessment of symptoms of post-traumatic stress disorder. The PCL-5 consists of 20 items, each rated on a scale from 0 to 4. The total score ranges from 0 to 80. Higher scores indicate a worse outcome, as they reflect greater severity of PTSD symptoms.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
The World Health Organization-Five Well-Being Index (WHO-5)
Assessment of subjective psychological well-being.The WHO-5 consists of 5 items, each rated on a scale from 0 to 5. Higher scores indicate a better outcome, as they reflect higher levels of well-being.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
Brief Resilience Scale (BRS)
Assessment of resilience.The BRS consists of 6 items, each rated on a scale from 1 to 5. Higher scores indicate a better outcome, as they reflect greater resilience.
Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention
Client Satisfaction Questionnaire (CSQ-3)
Assessment of the levels of satisfaction of the participant with the intervention.CSQ-3 consists of 3 items. Each item is rated on a scale from 1 to 4. Higher scores indicate a better outcome, as they reflect greater satisfaction with the services received.
Time frame: Immediately after the intervention, 6 months after completion of the intervention
Ran from Mar 2025 to primary completion in Mar 2026, 12 months.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 12 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2026 → Mar 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.